Physician profile
Aman Mongia
NPI 1235101072
$9,361.49
in general payments reported to CMS, 2019-2025
33 companies · $851 in 2025
The $851 reported for 2025 was more than what 76% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,887 · 2020: $1,458 · 2021: $1,243 · 2022: $920 · 2023: $1,195 · 2024: $806 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,830 · Consulting Fee: $22.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,829.92 |
| Consulting Fee | $22.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $2,556.57 | 2019-2025 | Nuzyra |
| Viiv Healthcare Company | $1,057.02 | 2019-2025 | Cabenuva, Dovato, Rukobia |
| Gilead Sciences, INC. | $943.56 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $491.66 | 2023-2024 | Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $446.08 | 2021-2025 | Cuvitru, Glassia |
| Insmed, INC. | $344.99 | 2020-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $331.40 | 2019-2023 | |
| Medicines360 | $300.00 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $294.32 | 2020-2025 | Vibativ |
| Octapharma USA, INC. | $251.39 | 2019-2023 | Cutaquig |
| Grifols USA, LLC | $213.40 | 2020-2024 | Xembify |
| Allergan, INC. | $208.93 | 2019-2020 | |
| Janssen Biotech, INC. | $194.76 | 2019-2021 | |
| Melinta Therapeutics, LLC | $178.72 | 2019-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Emd Serono, INC. | $167.17 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Products, LP | $155.98 | 2019-2020 | |
| Theratechnologies INC. | $140.03 | 2020-2024 | Egrifta, Trogarzo |
| Abbvie INC. | $128.74 | 2021-2025 | |
| Pfizer INC. | $126.31 | 2022-2025 | |
| Axsome Therapeutics, INC. | $125.00 | 2025 | Auvelity |
| Csl Behring | $111.06 | 2022-2025 | Hizentra |
| Tetraphase Pharmaceuticals, INC. | $110.40 | 2019-2025 | |
| Genzyme Corporation | $100.61 | 2022-2023 | |
| Comsort, INC | $100.00 | 2019 | |
| La Jolla Pharmaceutical Company | $74.53 | 2021-2025 | Zevtera |
| Novartis Pharmaceuticals Corporation | $34.95 | 2023 | |
| Organogenesis INC. | $31.34 | 2024 | Puraply Am |
| Ionis Pharmaceuticals, INC. | $27.99 | 2025 | Dawnzera |
| Genentech USA, INC. | $26.31 | 2021 | |
| Ferring Pharmaceuticals INC. | $23.90 | 2023 | Rebyota |
| Adma Biomanufacturing LLC | $22.95 | 2023 | |
| Astellas Pharma US INC | $22.75 | 2022 | |
| Glaxosmithkline, LLC. | $18.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aman Mongia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.